Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery

Kuang, H., Ku, S. H., & Kokkoli, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.08.005 · Cited by 66

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

Baraibar, I., Mezquita, L., Bazo, I. G., & Planchard, D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102906 · Cited by 69

Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States

Ting, J., Tien Ho, P., Xiang, P., Sugay, A., Abdel-Sattar, M., & Wilson, L. (2015) · Value in Health · doi:10.1016/j.jval.2015.04.008 · Cited by 65

Nanoparticle-based targeted gene therapy for lung cancer.

Lee, H.-Y., Mohammed, K. A., & Nasreen, N. (2016) · PubMed Central · Cited by 65

Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancer

Hong, W., Wu, Q., Zhang, J., & Zhou, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10715 · Cited by 67

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 67

Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress

Sharma, B., Singh, V. J., & Chawla, P. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105393 · Cited by 65

Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes

Skora, A. D., Douglass, J., Hwang, M. S., Tam, A. J., Blosser, R. L., Gabelli, S. B., Cao, J., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511996112 · Cited by 67

Mechanisms of resistance to EGFR targeted therapies

Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

Hanan, E. J., Eigenbrot, C. W., Bryan, M. C., Burdick, D. J., Chan, B. K., Chen, Y., Dotson, J., Heald, R. A., Jackson, P. S., La, H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501578n · Cited by 65

Personalized Therapy for Lung Cancer

Moreira, A. L., & Eng, J. (2014) · CHEST Journal · doi:10.1378/chest.14-0713 · Cited by 67

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., Burgess, K., Qiu, M., Engstrom, L. D., Yamazaki, S., Parker, M., Timofeevski, S. L., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0839 · Cited by 66

Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor

Mallon, R. G., Hollander, I. J., Feldberg, L. R., Lucas, J., Soloveva, V., Venkatesan, A. M., Dehnhardt, C. M., Santos, E. D., Chen, Z., dos Santos, O., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0954 · Cited by 65

Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer

Suzuki, A., Suzuki, M., Mizushima‐Sugano, J., Frith, M. C., Makałowski, W., Kohno, T., Sugano, S., Tsuchihara, K., & Suzuki, Y. (2017) · DNA Research · doi:10.1093/dnares/dsx027 · Cited by 65

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells

Chen, Z., Tian, D., Liao, X., Zhang, Y., Xiao, J., Chen, W., Liu, Q., Chen, Y., Li, D., Zhu, L., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00260 · Cited by 66

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Truini, A., Starrett, J. H., Stewart, T. F., Ashtekar, K. D., Walther, Z., Wurtz, A., Lu, D. M., Park, J. H., DeVeaux, M., Song, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0780 · Cited by 66

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

Lamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 66

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer

Mao, C., Yuan, J.-Q., Yang, Z., Fu, X., Wu, X., & Tang, J.-L. (2015) · Medicine · doi:10.1097/md.0000000000000775 · Cited by 64

MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression

Pan, D., Jiang, C., Ma, Z., Blonska, M., You, M. J., & Lin, X. (2015) · Oncogene · doi:10.1038/onc.2015.146 · Cited by 67

Mass Spectrometry Mapping of Epidermal Growth Factor Receptor Phosphorylation Related to Oncogenic Mutations and Tyrosine Kinase Inhibitor Sensitivity

Zhang, G., Fang, B., Liu, R. Z., Lin, H., Kinose, F., Bai, Y., Oguz, U., Remily-Wood, E. R., Li, J., Altiok, S., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr1006203 · Cited by 64

Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib

Ma, F., Sun, T., Shi, Y., Yu, D., Tan, W., Yang, M., Wu, C. H., Chu, D.-T., Sun, Y. P., Xu, B., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.12.025 · Cited by 64

Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering

Han, X., Cinay, G. E., Zhao, Y., Guo, Y., Zhang, X., & Wang, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.009 · Cited by 65

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65

Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide

He, K., Zhang, Z., Wang, W., Zheng, X., Wang, X., & Zhang, X. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127167 · Cited by 65

Adaptive response of resistant cancer cells to chemotherapy

Chern, Y., & Tai, I. T. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0005 · Cited by 67

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling

WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64

Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo

Lee, J. G., & Wu, R. (2015) · Neoplasia · doi:10.1016/j.neo.2014.12.008 · Cited by 64

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review

Murphy, M. P., & Stordal, B. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.004 · Cited by 63

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Heald, R. A., Bowman, K. K., Bryan, M. C., Burdick, D. J., Chan, B. K., Chan, E. W., Chen, Y., Clausen, S., Dominguez‐Fernandez, B., Eigenbrot, C. W., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01412 · Cited by 63

Diagnostic Molecular Biomarkers for Malignant Pleural Effusions

Sriram, K. B., Relan, V., Clarke, B. E., Duhig, E., Yang, I. A., Bowman, R., Lee, G., & Fong, K. M. (2011) · Future Oncology · doi:10.2217/fon.11.45 · Cited by 62

Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations

Lund‐Iversen, M., Kleinberg, L., Fjellbirkeland, L., Helland, Å., & Brustugun, O. T. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182614a9d · Cited by 62

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib

Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 63

High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma

Lee, Y., Shim, H. S., Park, M. S., Kim, J.-H., Ha, S., Kim, S. H., & Cho, B. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2582 · Cited by 62

c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential

Marcotte, R., Zhou, L., Kim, H. L., Roskelly, C. D., & Muller, W. J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01731-08 · Cited by 62

Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition

Choe, C., Shin, Y.-S., Choi, S., Lee, J., Kim, S. Y., Cho, Y. B., Kim, J., & Kim, C. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89659 · Cited by 64

G Protein-Coupled Receptor Signaling in Stem Cells and Cancer

Lynch, J., & Wang, J. Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050707 · Cited by 62

Oxymatrine inhibits non–small cell lung cancer via suppression of EGFR signaling pathway

Li, W., Yu, X., Tan, S., Liu, W., Zhou, L. Q., & Liu, H. (2017) · Cancer Medicine · doi:10.1002/cam4.1269 · Cited by 63

EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis

Benbrahim, Z., Antonia, T., & Mellas, N. (2018) · BMC Cancer · doi:10.1186/s12885-018-4774-y · Cited by 62

A Panel of High Resolution Melting (HRM) Technology-Based Assays with Direct Sequencing Possibility for Effective Mutation Screening of EGFR and K-ras Genes

Heideman, D. A. M., Thunnissen, E., Doeleman, M., Kramer, D., Verheul, H. M. W., Smit, E. F., Postmus, P. E., Meijer, C. J. L. M., Meijer, G. A., & Snijders, P. J. F. (2009) · Analytical Cellular Pathology · doi:10.1155/2009/465850 · Cited by 62

Resistance to molecularly targeted therapy in non-small-cell lung cancer

Asao, T., Takahashi, F., & Takahashi, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.09.001 · Cited by 62

Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis

Zhao, Y., Cheng, B., Chen, Z., Li, J., Liang, H., Chen, Y., Zhu, F., Li, C., Xu, K., Xiong, S., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103305 · Cited by 65

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations

Duggirala, K. B., Lee, Y., & Lee, K. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2021.047 · Cited by 62

Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects

Qureshi, R., Zou, B., Alam, T., Wu, J., Lee, V. H.-F., & Yan, H. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3141697 · Cited by 61

Cost-Effective Fiber Optic Solutions for Biosensing

Leitão, C., Pereira, S. O., Marques, C., Cennamo, N., Zeni, L., Shaimerdenova, M., Ayupova, T., & Tosi, D. (2022) · Biosensors · doi:10.3390/bios12080575 · Cited by 61

E3 ligase ligand optimization of Clinical PROTACs

Jiang, H., Xiong, H., Gu, S.-X., & Wang, M. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1098331 · Cited by 64

Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer

Heuckmann, J. M., Rauh, D., & Thomas, R. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1825 · Cited by 61

Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor

Pawar, V. G., Sos, M. L., Rode, H. B., Rabiller, M., Heynck, S., van Otterlo, W. A. L., Thomas, R. K., & Rauh, D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901877j · Cited by 61

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer

Kaira, K., Naito, T., Takahashi, T., Ayabe, E., Shimoyama, R., Kaira, R., Ono, A., Igawa, S., Shukuya, T., Murakami, H., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.006 · Cited by 61

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification

Yoshida, T., Okamoto, I., Okamoto, W., Hatashita, E., Yamada, Y., Kuwata, K., Nishio, K., Fukuoka, M., Janne, P. A., & Nakagawa, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01368.x · Cited by 61

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

Doebele, R. C., Oton, A. B., Peled, N., Camidge, D. R., & Bunn, P. A. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.12.009 · Cited by 62

Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells

Li, F., Mei, H., Xie, X., Zhang, H., Liu, J., Lv, T., Nie, H., Gao, Y., & Jia, L. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0057-9 · Cited by 61

Tumor Inhibition Achieved by Targeting and Regulating Multiple Key Elements in EGFR Signaling Pathway Using a Self‐Assembled Nanoprodrug

Li, B., Xie, X., Chen, Z., Zhan, C., Zeng, F., & Wu, S. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201800692 · Cited by 60

High‐Performance Nucleic Acid Sensors for Liquid Biopsy Applications

Das, J., & Kelley, S. O. (2019) · Angewandte Chemie · doi:10.1002/ange.201905005 · Cited by 60

Development of c-MET pathway inhibitors

Liu, X., Newton, R. C., & Scherle, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.600687 · Cited by 60

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

Wu, X., Wanders, A., Wardęga, P., Tinge, B., Gedda, L., Bergström, S. N., Sooman, L., Gullbo, J., Bergqvist, M., Hesselius, P., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604855 · Cited by 60

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

Spicer, J. F., & Rudman, S. M. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0140-y · Cited by 61

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

Whang, Y. M., Park, S. I., Trenary, I. A., Egnatchik, R. A., Fessel, J. P., Kaufman, J., Carbone, D. P., & Young, J. D. (2015) · Oncogene · doi:10.1038/onc.2015.140 · Cited by 60

The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer

Ray, M., Salgia, R., & Vokes, E. E. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0054 · Cited by 60

IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer

Manabe, T., Yasuda, H., Terai, H., Kagiwada, H., Hamamoto, J., Ebisudani, T., Kobayashi, K., Masuzawa, K., Ikemura, S., Kawada, I., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0956 · Cited by 60

Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience

Mellstedt, H., Vansteenkiste, J., & Thatcher, N. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.023 · Cited by 61

Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop

Zhang, C., Zhou, W., Xu, H., Xu, J., Li, J., Liu, X., Lu, X., Dai, J., Jiang, Y., Wang, W., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03318-y · Cited by 59

Structural Optimization and Structure–Activity Relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations

Yang, J., Wang, L., Liu, J., Zhong, L., Zheng, R., Xu, Y., Ji, P., Zhang, C., Wang, W., Lin, X., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301365e · Cited by 59

Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers

Busser, B., Sancey, L., Josserand, V., Niang, C., Favrot, M., Coll, J., & Hurbin, A. (2009) · Molecular Therapy · doi:10.1038/mt.2009.226 · Cited by 59

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

Rukazenkov, Y., Speake, G., Marshall, G. B., Anderton, J., Davies, B. R., Wilkinson, R. W., Hickinson, D. M., & Swaisland, A. J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833034e1 · Cited by 59

Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer

Kono, S. A., Heasley, L. E., Doebele, R. C., & Camidge, D. R. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799095144 · Cited by 59

Aptamer-functionalized graphene oxide for highly efficient loading and cancer cell-specific delivery of antitumor drug

Lu, Y., Wu, P., Yin, Y., Zhang, H., & Cai, C. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb00521j · Cited by 59

CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation

Liu, B., Su, Y., Li, T., Yuan, W., Mo, X., Li, H., He, Q., Ma, D., & Han, W. (2015) · Oncotarget · doi:10.18632/oncotarget.5732 · Cited by 59

Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents

Bagul, C., Rao, G. K., Makani, V. K. K., Tamboli, J. R., Pal‐Bhadra, M., & Kamal, A. (2017) · MedChemComm · doi:10.1039/c7md00193b · Cited by 59

Altered conformational landscape and dimerization dependency underpins the activation of EGFR by α C– β 4 loop insertion mutations

Ruan, Z., & Kannan, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803152115 · Cited by 59

Targeted therapies for advanced non-small cell lung cancer

Ai, X., Guo, X., Wang, J., Stancu, A. L., Joslin, P. M. N., Zhang, D., & Zhu, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26428 · Cited by 60

In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation

Patel, H., Ahmad, I., Pawara, R. H., Shaikh, M., & Surana, S. J. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1734092 · Cited by 60

Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway

Han, Z., Zhou, X., Li, S., Qin, Y., Chen, Y., & Liu, H. (2017) · Oncology Reports · doi:10.3892/or.2017.5938 · Cited by 58

Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants

Zhao, Z., Xie, L., & Bourne, P. E. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00458 · Cited by 59

Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application

Maione, P., Sacco, P. C., Sgambato, A., Casaluce, F., Rossi, A., & Gridelli, C. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015595048 · Cited by 59

IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype

Cadranel, J. L., Quoix, É., Baudrin, L., Mourlanette, P., Moro‐Sibilot, D., Morère, J., Souquet, P.-J., Soria, J., Morin, F., & Milleron, B. J. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181abeb5d · Cited by 58

Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest

Kriegs, M., Gurtner, K., Can, Y., Brammer, I., Rieckmann, T., Oertel, R., Wysocki, M., Dorniok, F., Gal, A., Grob, T. J., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.018 · Cited by 58

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications

Marchetti, A., Grammastro, M. D., Filice, G., Felicioni, L., Rossi, G., Graziano, P., Sartori, G., Leone, A., Malatesta, S., Iacono, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042164 · Cited by 59

Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making

Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling

Daly, C., Castanaro, C., Zhang, W., Zhang, Q., Wei, Y., Ni, M., Young, T. M., Zhang, L., Burova, E., & Thurston, G. (2016) · Oncogene · doi:10.1038/onc.2016.216 · Cited by 58

The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer

Zhang, J., Liu, S., Li, Q., Shi, Y., Wu, Y., Liu, F., Wang, S., Zaky, M. Y., Yousuf, W., Sun, Q., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0538-8 · Cited by 59

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC

Zeng, H., Castillo-Cabrera, J., Manser, M., Lu, B., Yang, Z., Strande, V., Begue, D., Zamponi, R., Qiu, S., Sigoillot, F., et al. (2019) · eLife · doi:10.7554/elife.50223 · Cited by 57

The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer

Fan, Q., Wang, Q., Cai, R., Yuan, H., & Xu, M. (2020) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0193-6 · Cited by 58

Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion

Whitsett, T. G., Cheng, E., Inge, L. J., Asrani, K. V., Jameson, N. M., Hostetter, G. H., Weiss, G. J., Kingsley, C. B., Loftus, J. C., Bremner, R. M., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.026 · Cited by 58

EGFR and KRAS mutations in metastatic lung adenocarcinomas

Munfus-McCray, D., Harada, S., Adams, C., Askin, F. B., Clark, D. P., Gabrielson, E., & Li, Q. K. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.12.011 · Cited by 57

Limited copy number - high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies

Do, H., & Dobrovic, A. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-82 · Cited by 59

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer

Zhang, K., & Yuan, Q. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.200613 · Cited by 57

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer

Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 59

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance

Ma, Y., Zheng, X. X., Zhao, H., Fang, W., Zhang, Y., Ge, J., Wang, L., Wang, W., Jiang, J., Chuai, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.025 · Cited by 57

CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance

Gu, X., Qiu, Y., Lin, M., Cui, K., Chen, G., Chen, Y., Fan, C., Zhang, Y., Xu, L., Chen, H., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01065 · Cited by 58

Polygonatum cyrtonema lectin induces murine fibrosarcoma L929 cell apoptosis and autophagy via blocking Ras–Raf and PI3K–Akt signaling pathways

Liu, B., Wu, J., Li, J., Liu, J., Li, W., Li, C., Xu, H., & Bao, J. (2010) · Biochimie · doi:10.1016/j.biochi.2010.08.009 · Cited by 57

Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated With Lung Cancer With Squamous Differentiation

van Noesel, J., van der Ven, W. H., van Os, T. A. M., Kunst, P. W. A., Weegenaar, J., Reinten, R. J. A., Kancha, R. K., Duyster, J., & van Noesel, C. J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1586 · Cited by 57

Genes and Pathology of Non-Small Cell Lung Carcinoma

Sakashita, S., Sakashita, M., & Tsao, M. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.008 · Cited by 56

Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs

Tao, L., Zhu, F., Xu, F., Chen, Z., Jiang, Y., & Chen, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.019 · Cited by 56

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

Ballas, & Chachoua (2011) · OncoTargets and Therapy · doi:10.2147/ott.s18155 · Cited by 57

Gene network dynamics controlling keratinocyte migration

Busch, H. S., Camacho‐Trullio, D., Rogon, Z., Breuhahn, K., Angel, P. E., Eils, R., & Szabowski, A. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.36 · Cited by 56

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project—Part 1)

Beau‐Faller, M., Degeorges, A., Rolland, E., Mounawar, M., Antoine, M., Poulot, V., Mauguen, A., Barbu, V., Coulet, F., Prétet, J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318211dcee · Cited by 56

MicroRNAs in pancreatic cancer metabolism

Singh, P. K., Brand, R. E., & Mehla, K. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.63 · Cited by 59

Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update

Ahsan, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_7 · Cited by 56

Curcumin Lowers Erlotinib Resistance in Non-Small Cell Lung Carcinoma Cells With Mutated EGF Receptor

Li, S., Liu, Z., Zhu, F., Fan, X., Wu, X., Zhao, H., & Jiang, L. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13832473330032 · Cited by 57

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156